Minnesota Hormone Therapy Lawsuit Dismissed
MADISON, N.J., October 30, 2007 /PRNewswire-FirstCall/ -- Wyeth announced today that The Honorable George F. McGunnigle of the Hennepin County District Court in Minneapolis, Minnesota has granted Wyeth's motion for summary judgment on all claims and dismissed the case of Patricia Zandi v. Wyeth, which was scheduled for trial on January 28, 2008. In rulings on the admissibility of plaintiff's expert testimony and on the motion for summary judgment, the court found that the plaintiff had not offered any scientifically valid evidence to support her claim that she developed breast cancer as a result of her use of Premarin(R) and Prempro(TM).
Judge McGunnigle held that plaintiff had "provided no evidence of a method generally accepted in the scientific community by which a doctor can determine the cause of breast cancer in an individual."
"In this case," the court elaborated, plaintiff's experts "purported to make a differential diagnosis. However, their attempt at differential diagnosis fails and is unreliable." The court concluded that "the scientific community has not accepted that breast cancer has a limited number of discrete and recognized possible causes such that ruling out one cause would implicate another."
"We are pleased with the Court's ruling and believe it was consistent with the body of scientific knowledge concerning hormone therapy and a proper application of the law," says Rebecca E. Moos, a partner with Bassford Remele, a Minneapolis firm representing Wyeth in the case.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
CONTACT: Media Contact: Douglas Petkus, +1-973-660-5218, or InvestorContact: Justin Victoria, +1-973-660-5340, both of Wyeth
Ticker Symbol: (NYSE:WYE)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: October 2007